Insights Into HER2+ Breast Cancer Northwest

Perspectives on current treatment practices regarding HER2+ metastatic breast cancer, management of progressive HER2+ metastatic disease, and attitudes toward recently introduced and upcoming agents.

Northwest December 10, 2020

Faculty Chair

Ingrid Mayer, MD

Vanderbilt University Medical Center, Nashville, TN

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • An insights-generating meeting focusing on treatment of HER2+ breast cancer was held on December 10, 2020, in a virtual setting
  • Disease state and data presentations were developed in conjunction with Ingrid Mayer, MD, a medical expert from Vanderbilt University Medical Center
  • Insights on the following therapies were obtained: trastuzumab (and biosimilars), lapatinib, pertuzumab, T-DM1, neratinib, tucatinib, trastuzumab deruxtecan, AIs, and chemotherapies

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • Attendees of the roundtable represented community oncologists from California, Washington, Oregon, and Wyoming

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.